Skip to main content

Market Overview

BioDelivery Sciences Awarded Patent Resulting in $15 Million Milestone Payment


BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that the U.S. Patent and Trademark Office (USPTO) has formally awarded BDSI's patent No. 13/184306, "Transmucosal Delivery Devices with Enhanced Uptake," which extends the patent protection for BDSI's BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven years to 2027. The USPTO had issued a Notice of Allowance to BDSI for this patent as previously disclosed in February of this year.

BDSI now confirms that the $15 million milestone associated with its licensing and development agreement with Endo Pharmaceuticals for BEMA Buprenorphine is payable, bringing the total milestone payments received thus far to $45 million.


Related Articles (BDSI)

View Comments and Join the Discussion!

Posted-In: News Contracts Legal

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at